Learn the Latest Research on Prostate Cancer Treatments
At Precision Prostate Cancer Care, we believe an educated patient is an empowered patient. Much of the information you may encounter online is biased or misleading. Some of it even points patients toward “state of the art” surgery or radiation that in many cases is not necessary. E. David Crawford, MD, has authored or co-authored numerous peer-reviewed research studies. Below, you will find research articles and news that present the most current prostate cancer diagnostic and treatment standards and research findings, including some of Dr. Crawford’s recent studies.
A Better Method for Determining the Stage and Spread of Prostate Cancer?
Traditional diagnostic methods such as 12-core ultrasound often miss prostate cancer that has spread, or fail to detect the extent of cancer’s spread. In this study, researchers including E. David Crawford, MD, of Precision Prostate Cancer Care, compared diagnostic methods for determining the stage and spread of cancer. They found that Transperineal 3-dimensional mapping biopsy (3DMB) provided a more accurate depiction of disease status. Read more.
Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.
This purpose of this study was to evaluate whether prostate cancer screening had an effect on prostate cancer deaths. Two previous studies had produced conflicting results; this study delved further into the each of the studies and provided a more detailed evaluation. The researchers concluded that prostate cancer screening did reduce mortality. Read more.
Navigating the Evolving Therapeutic Landscape in Advanced Prostate Cancer.
Prostate cancer is the most common cancer in men, with 137.9 new cases per 100,000 men each year. The overall 5-year survival rate for prostate cancer is very high. Nevertheless, up to 20% of men who undergo state-of-the art treatment for prostate cancer will develop prostate cancer that progresses despite androgen-depletion therapy. With the advent of several new drugs in the past five years to treat this drug-resistant prostate cancer, the challenge facing clinicians is how to best sequence or combine therapies or both to produce the best outcomes. A better understanding of the disease process and the role of the androgen receptor as a target for both therapy and resistance have led to the consideration of biomarkers as an approach to aid in selecting the appropriate agent. Research to identify new prognostic biomarkers, which are associated with outcome measures, as well as predictive biomarkers, which predict response or resistance to therapy is ongoing. The treatment of advanced prostate cancer and the research related to biomarkers are discussed. Read more.
An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care.
There has been widespread disagreement in the medical community about the best approach to routine screening for prostate cancer. In this paper, researchers presented an alternative approach in which screening is performed for men with at least a 10-year life expectancy. If the Prostate Specific Antigen (PSA) is less than 1.5ng/ml, consider re-screening in five years. If the PSA is ≥ 1.5ng/ml, or the primary care physician identifies an abnormality through digital rectal exam, the authors suggest referral to a specialist or consideration of a biomarker to assess risk more precisely. In the study algorithm, researchers recommend that a biopsy should not be performed unless the risk of an aggressive tumor is significant, and following a thorough discussion of benefits and risks with the patient. These discussions should emphasize that the purpose of screening is the early identification of potentially lethal disease, and that in most cases low-risk tumors, if identified, do not require immediate treatment. A potential benefit of this approach is that it could greatly reduce the number of men requiring shared decision-making and further testing to those at greater risk of significant prostate cancer. Read more.
Focal Therapy in Prostate Cancer: Future Trends
BJU International 2005
Early detection has resulted in a proportionally significant increase in the diagnosis of prostate cancer in many men with clinically insignificant disease, based on cancer volume (<1 mL) and slower growth rate. According to one report, 30–40% of men aged >50 years have prostate cancer, but only 8% of cancers become clinically significant. Even so, many of the recommended treatments for prostate cancer, such as radical prostatectomy, are fairly aggressive, and patients frequently ask why the urologist cannot treat just the diseased part of their prostate. Learn more about trends in targeted focal cryotherapy treatment for prostate cancer, a minimally-invasive treatment that preserves healthy prostate tissue and reduces side effects. Read more.